Invesco Biotechnology & Genome ETF (PBE) Stock Price & Analysis
Invesco Biotechnology & Genome ETF (PBE) closed at USD 98.72 on Friday, October 23, 2026, down 0.67% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 99.38; the Oct 23, 2026 session ranged USD 97.57–98.72 on volume of 7,709 shares. Market capitalization is —, with a 52-week range of USD 72.27–99.99 (PCX). Source: Nexqual, retrieved October 24, 2026 at 14:09 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PBE.md
Key facts (PBE)
- Total return with dividends: 1Y +36.6% vs S&P 500 +13.4%; 5Y +34.5% vs S&P 500 +76.9%.
Total return (dividends reinvested) (PBE)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +36.6% | +34.5% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +36.8% | +6.1% |
| Volatility (annualized) | 19.8% | 21.6% |
| Max drawdown | -11.7% (Jan 2026→Mar 2026) | -30.0% (Oct 2021→Oct 2023) |
PBE options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 27 | 28.4% | ±6.3% |
| Dec 18, 2026 | 55 | 26.7% | ±8.5% |
| Mar 19, 2027 | 146 | 21.5% | ±10.8% |
| Jun 17, 2027 | 236 | 21.6% | ±13.9% |
30-day implied volatility 26% vs 23.2% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 24, 2026 at 14:09 UTC)
| Price | USD 98.72 |
|---|---|
| Change | ▼ 0.67% (down) |
| Previous Close | USD 99.38 |
| Open | USD 97.57 |
| Day Range | USD 97.57 – 98.72 |
| 52-Week Range | USD 72.27 – 99.99 |
| Volume | 7,709 shares |
| Market Cap | — |
| Exchange | PCX |
Technical Analysis (PBE)
Nexqual's technical model rates PBE "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 24, 2026 at 14:09 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.01 (neutral) |
| vs SMA50 | Above (USD 96.41) |
| MACD | 0.86 (positive) |
Financial Health Score (PBE)
Nexqual rates Invesco Biotechnology & Genome ETF's overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 14:09 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Mixed — No data |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PJP | Invesco Pharmaceuticals ETF | USD 125.03 | ▼ 1.79% |
| FBT | First Trust Amex Biotech Index | USD 269.25 | ▼ 1.26% |
| PBJ | Invesco Food & Beverage ETF | USD 47.93 | ▼ 1.03% |
| PKB | Invesco Building & Construction | USD 85.44 | ▼ 1.33% |
| BBH | VanEck Biotech ETF | USD 246.57 | ▼ 0.74% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 14:09 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt